BAMF
MDGL icon

BI Asset Management Fondsmaeglerselskab’s Madrigal Pharmaceuticals MDGL Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-146
Closed -$48K – 850
2025
Q1 		$48K Sell
146
-385
-73% -$127K ﹤0.01% 802
2024
Q4 		$164K Buy
+531
New +$149K ﹤0.01% 698
2023
Q2 		– Sell
-793
Closed -$192K – 775
2023
Q1 		$192K Buy
+793
New +$216K 0.01% 592

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's MDGL Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 146 shares — an estimated $48K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in MDGL in Q1 2023 and held it in 3 quarters. The position peaked at $192K in Q1 2023. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 146 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $48K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • BI Asset Management Fondsmaeglerselskab's Madrigal Pharmaceuticals position peaked at $192K in Q1 2023.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.